Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy

Data showing overall survival benefit for Keytruda in patients with at least 1% PD-L1 expression ups the ante for competitors...

      

Related Stories

• AstraZeneca's License Of Ionis NASH Candidate Illustrates Still Hot Competition
• Roche Seen Offering NICE Further Price Cut For MS Drug Ocrevus
• Roche Offering NICE Further Price Cut For MS Drug Ocrevus

 

Original Article: Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy

More From BioPortfolio on "Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy"